Clinical trials: Repigmentation

Vitiligo, Repigmentation

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

• Withdrawn
• Age: 10 to 40 years
• Phase 4

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives…

Trial name

NCT01202513

Testing

Bimatoprost 0.03% topical ophthalmic solution

Volunteers

20 people

Sponsor

Gian Sagar Medical College and Hospital